Dupixent (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal…
The European Commission (EC) approved a new indication for Dupixent (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with…
Read More...
Read More...
